Risks and benefits associated with novel phase 1 oncology trial designs.
about
Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatmentEvaluation of agile designs in first-in-human (FIH) trials--a simulation studyPhase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worseExtending clinical equipoise to phase 1 trials involving patients: unresolved problemsDose escalation methods in phase I cancer clinical trials.First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless.Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?Discrete event simulation applied to pediatric phase I oncology designs.Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.Moral justification of Phase 1 oncology trials.Risks and benefits of phase 1 clinical trial participation.Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?How to keep high-risk studies ethical: classifying candidate solutions.Design issues in dose-finding Phase I trials for combinations of two agents.Some notable properties of the standard oncology Phase I design.Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.Phase I trials involving radiation therapy, quantifying the risks.Better to be in The Placebo Arm for Trials of Neurological Therapies?
P2860
Q28740828-076ACDC2-0D09-4DCB-9370-A73D13941ADEQ30491850-81AFE90A-7F5D-4839-B284-7AEC1C52A718Q33658203-ACB7BED8-681B-41C6-BDF6-1FA9956DF674Q35788038-58AF5D8F-18A6-4A63-818D-B0B15ACDD004Q37198192-D5220A62-33BD-4C0D-B94E-B044DB54FE77Q37217591-64C68CAF-6892-40E2-BB25-6EC730E6C59DQ37222606-66B738A9-706E-4973-8F4B-CA16602844C2Q37299233-3C30A4A0-8C5C-4955-BFB9-9F856E556E1DQ37383697-8381C2D8-F1A2-405A-882B-1848979CF1A2Q38210627-659AE731-9014-4D24-8E55-68221152143FQ38222465-2B1AB97A-3A4E-40DD-BB01-62FC87D675F1Q40025547-DDEE4852-0DBB-49BB-8FC2-56C978992027Q42355200-9E0ECD64-280C-48D3-AB60-499A95CB0568Q43409313-22230FA6-9E63-4068-B023-66557D91D7A4Q45978270-194E3318-2468-451D-87FB-532273D233A7Q51640753-2CE7A3B7-DF57-466A-B515-0B3A2CE97021Q54526137-88E5F8C0-E1C4-44D0-B64C-BD6FDABAA26AQ55642155-12ED01A2-4506-48FA-A1D4-489945C3011D
P2860
Risks and benefits associated with novel phase 1 oncology trial designs.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Risks and benefits associated with novel phase 1 oncology trial designs.
@en
type
label
Risks and benefits associated with novel phase 1 oncology trial designs.
@en
prefLabel
Risks and benefits associated with novel phase 1 oncology trial designs.
@en
P2093
P2860
P356
P1433
P1476
Risks and benefits associated with novel phase 1 oncology trial designs.
@en
P2093
Benjamin Krohmal
Cary P Gross
Elizabeth Garrett-Mayer
Elizabeth Wolf
Manish Agrawal
Shlomo A Koyfman
P2860
P304
P356
10.1002/CNCR.22878
P407
P577
2007-09-01T00:00:00Z